<DOC>
	<DOCNO>NCT00740948</DOCNO>
	<brief_summary>CLINICAL PHASE II INDICATION Sjogren 's syndrome RATIONALE Sjögren 's syndrome ( SS ) autoimmune disorder affect 0.2 % 3 % general population . Pharmacological treatment improve sicca symptom , often transiently , unable modify course disease.Open label study suggest low-dose rituximab produce acute complete CD20 depletion blood tissue ; well tolerate without corticosteroid use ; significantly improve glandular extra-glandular manifestation pSS . Larger control study warrant . Our hypothesis two infusion 1000 mg Rituximab may better placebo treat patient suffer pSS . To test hypothesis , propose compare patient recent and/or severe pSS treat either Rituximab placebo . OBJECTIVES Primary objective : Evaluation efficacy define 30 % improvement Day 1 Week 24 value 2 4 VAS measure global score disease ( activity disease include extra glandular manifestation ) , joint pain , fatigue , disturb dryness.Secondary objective : Variations baseline week 24 : The 0-100-mm VAS score dry mouth , dry eye , dry trachea , dry vagina , dry skin ; fatigue ; pain ; Tender swell joint count ; Tender point ; Other systemic manifestation ; Unstimulated salivary flow rate ; Schirmer van Bijsterveld score ( 2-3 ) ; C-reactive protein ( CRP ) erythrocyte sedimentation rate ( ESR ) ; rheumatoid factor ( RF ) ; ANA ; serum IgG , IgA , IgM ; complement ; cryoglobulinemia ; count B T cell ; Evaluation safety Rituximab study Evaluation improvement evaluate VAS physician Evaluation disease activity score suggest Bowman Vitali Evaluation Chisholm score , B cell characteristic DNA microarray labial accessory salivary gland ( SG ) biopsy sample , salivary gland echography inclusion week 24 . TRIAL DESIGN Multicenter , randomize , double-blind , placebo-controlled trial NUMBER OF SUBJECTS : 120</brief_summary>
	<brief_title>Tolerance Efficacy Rituximab Sjogren 's Disease</brief_title>
	<detailed_description>TARGET POPULATION Inclusion criterion : Patients eligible : fulfill new American-European Consensus Group criteria pSS : - recent ( less 10 year ) active disease assess : - value &gt; 50 mm 2 4 visual analogue scale ( VAS ) ( 0-100mm ) evaluate global score disease ( activity disease include extra glandular manifestation ) , pain , sicca syndrome fatigue last week . - Rheumatoid factor SSA &gt; 1.5N cryoglobulinemia hypergammaglobulinemia high level beta2 microglobulinemia hypocomplémentemia . - and/or least one follow severe sign : parotidomegaly , arthritis , purpura , pulmonary involvement , tubulopathy , neurological involvement , thrombocytopenia . Additional inclusion criterion follow : - inform consent - age 18-80 year , - stable non-steroidal anti-inflammatory drug - prescription immunosuppressive agent least 4 week prior inclusion - Use reliable mean contraception ( patient reproductive potential ) Exclusion criterion : Patients exclude secondary SS , receive cytotoxic drug previous 4 month , severe renal haematological failure , history cancer , hepatitis B C , HIV , tuberculosis , severe diabetes chronic disease evidence infection , severe allergic anaphylactic reaction humanize murine monoclonal antibody unable understand protocol . Other : neutrophil count &lt; 1.5 x 103/L , live/attenuated vaccine within 28 day prior baseline , pregnancy , breast feeding ,</detailed_description>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>fulfill new AmericanEuropean Consensus Group criteria pSS : recent ( less 10 year ) active disease assess : value &gt; 50 mm 2 4 visual analogue scale ( VAS ) ( 0100mm ) evaluate global score disease ( activity disease include extra glandular manifestation ) , pain , sicca syndrome fatigue last week . Rheumatoid factor anti SSA &gt; 1.5N cryoglobulinemia hypergammaglobulinemia high level beta2 microglobulinemia hypocomplémentemia . and/or least one follow severe sign : parotidomegaly , arthritis , purpura , pulmonary involvement , tubulopathy , neurological involvement , inform consent age 1880 year , stable nonsteroidal antiinflammatory drug prescription immunosuppressive agent least 4 week prior inclusion Use reliable mean contraception ( patient reproductive potential ) Patients exclude secondary SS , receive cytotoxic drug previous 4 month , severe renal haematological failure , history cancer , hepatitis B C , HIV , tuberculosis , severe diabetes chronic disease evidence infection , severe allergic anaphylactic reaction humanize murine monoclonal antibody unable understand protocol . Other : neutrophil count &lt; 1.5 x 103/L , live/attenuated vaccine within 28 day prior baseline , pregnancy , breast feeding ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Sjogren 's disease</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Treatment</keyword>
	<keyword>anti CD20</keyword>
</DOC>